We are pleased to invite you to our Shareholders’ General Meeting, which will be held on May 16, 2018 in the Onxeo head office. It will be a real opportunity to present the progress made by our R&D programs, to share our strategy with you and to answer your questions.
Today, your Company has a solid R&D portfolio in the particularly innovative fields of DNA-targeting and epigenetics, with AsiDNA™, its first-in-class tumor DNA repair inhibitor, belinostat and our decoy oligonucleotide platform platON™. We also have the expertise and the resources to carry out our development plan in the upcoming months. This plan will be articulated in particular around the phase I DRIIV, a major value inflexion point.
Given this year’s ongoing traffic disruption in France, in order to secure your vote we urge you to either use a postal vote or make the Chairman or a tierce person your proxy. Of course, this will not prevent you from participating in person at the general meeting if you wish, and these means of voting will also allow your vote to be taken into account on June 19, in the event of a second meeting, without any further action required on your behalf.